Overview
Pneumonitis refers to inflammation of lung tissue, which can result from various causes including immunotherapy, drug reactions, environmental exposures, and viral/bacterial infections. It presents with respiratory symptoms and can range from mild to life-threatening depending on the etiology and severity. 134567Diagnosis
Clinical Presentation: Fever, cough, dyspnea, and radiological findings such as ground-glass opacities.
Imaging: Chest CT scans often reveal characteristic patterns (e.g., ground-glass opacities, consolidation).
Laboratory Tests: Elevated inflammatory markers (e.g., CRP, ESR).
Specific Testing:
- Immunotherapy-related: Consider viral testing for COVID-19 to rule out concurrent infection 1.
- Drug-induced: Consider specific drug levels and discontinuation if suspected (e.g., amiodarone, nitrofurantoin).
- Infectious Causes: PCR, cultures, and serology for suspected pathogens (e.g., Legionella, HHV-6) 5.
Special Imaging: Gallium-67 scintigraphy may indicate amiodarone-induced pneumonitis 6.Management
First-line Treatments:
- Steroids: High-dose corticosteroids (e.g., prednisone 1-2 mg/kg/day) are often initial therapy 15.
- Immunosuppression: For steroid-refractory cases, consider second-line agents like infliximab, mycophenolate mofetil, or other immunosuppressive therapies 1.
Adjunctive Treatments:
- Antibiotics: For suspected bacterial co-infections (e.g., Legionella) 5.
- Supportive Care: Oxygen therapy, mechanical ventilation if respiratory failure occurs.
Drug-specific Management:
- Amiodarone: Discontinue if pneumonitis is suspected 36.
- Nitrofurantoin: Discontinue immediately and consider alternative antibiotics 7.Special Populations
Elderly: Increased susceptibility to severe forms, particularly with drug-induced pneumonitis 34.
Comorbidities: Presence of underlying lung disease or immunosuppression may exacerbate pneumonitis severity 15.Key Recommendations
Multidisciplinary Approach: Utilize input from medical oncology, pulmonology, infectious disease, and radiology for diagnosis and management of immune-related pneumonitis, especially during the COVID-19 pandemic (Evidence: Expert opinion) 1.
Early Viral Testing: Perform early COVID-19 testing to differentiate from IR-pneumonitis in patients with overlapping symptoms (Evidence: Expert opinion) 1.
Steroid Therapy: Initiate high-dose corticosteroids for suspected immune-related pneumonitis (Evidence: Expert opinion) 15.
Monitor Drug Levels: For drug-induced pneumonitis, monitor and consider discontinuation of offending agents like amiodarone or nitrofurantoin (Evidence: Expert opinion) 37.
Consider Gallium-67 Scintigraphy: Use Gallium-67 scans for early detection of amiodarone-induced pneumonitis (Evidence: Weak) 6.References
1 Naidoo J, Reuss JE, Suresh K, Feller-Kopman D, Forde PM, Mehta Steinke S et al.. Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management. Journal for immunotherapy of cancer 2020. link
2 . Pneumonitis and non steroidal antiandrogens. Prescrire international 2003. link
3 Polkey MI, Wilson PO, Rees PJ. Amiodarone pneumonitis: no safe dose. Respiratory medicine 1995. link90254-6)
4 Seidal K, Jörgensen N, Elinder CG, Sjögren B, Vahter M. Fatal cadmium-induced pneumonitis. Scandinavian journal of work, environment & health 1993. link
5 Russler SK, Tapper MA, Knox KK, Liepins A, Carrigan DR. Pneumonitis associated with coinfection by human herpesvirus 6 and Legionella in an immunocompetent adult. The American journal of pathology 1991. link
6 van Rooij WJ, van der Meer SC, van Royen EA, van Zandwijk N, Darmanata JI. Pulmonary gallium-67 uptake in amiodarone pneumonitis. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1984. link
7 Averbuch SD, Yungbluth P. Fatal pulmonary hemorrhage due to nitrofurantoin. Archives of internal medicine 1980. link